REVIEW

The expanded role of fatty acid metabolism in cancer: new aspects and targets

Ming Chen* and Jiaoti Huang*

Department of Pathology, Duke University School of Medicine, Duke Cancer Institute, Duke University, Durham, NC 27514, USA

*Correspondence: Ming Chen, ming.chen318@duke.edu; Jiaoti Huang, jiaoti.huang@duke.edu

Abstract
Cancer cells undergo metabolic reprogramming to support cell proliferation, growth, and dissemination. Alterations in lipid metabolism, and specifically the uptake and synthesis of fatty acids (FAs), comprise one well-documented aspect of this reprogramming. Recent studies have revealed an expanded range of roles played by FA in promoting the aggressiveness of cancer while simultaneously identifying new potential targets for cancer therapy. This article provides a brief review of these advances in our understanding of FA metabolism in cancer, highlighting both recent discoveries and the inherent challenges caused by the metabolic plasticity of cancer cells in targeting lipid metabolism for cancer therapy.

Key words: cancer; fatty acid metabolism; lipid metabolism; metabolic plasticity

Introduction
Lipids are a diverse group of hydrophobic biomolecules that include sterols, acylglycerols, phospholipids, and sphingolipids. Most lipids are synthesized from fatty acids (FAs), a family of molecules consisting of a terminal carboxyl group and a hydrocarbon chain of various carbon lengths and levels of saturation. In the past three decades, FAs have attracted increased research attention, and even some controversy, because of studies linking dietary fat in the Western diet to various human malignancies, including cancers of the colon, breast, and prostate.1–3 Meanwhile, other findings have linked endogenous FA synthesis to human cancer. In the 1980s, Ookhtens et al. used in vivo 14C labelling of the central carbon metabolism in Ehrlich ascites tumors to show that almost all esterified FAs in the tumors are derived from de novo synthesis, although they noted that tumor tissues also acquire small amounts of FAs from circulating blood.4 In the mid-1990s, Kuhajda et al. revealed that OA-519, a highly expressed tumor-specific antigen in human breast cancer, encodes fatty acid synthase (FASN),5 and since this landmark discovery, numerous studies have confirmed that many human cancers display aberrant activation of de novo FA synthesis. It now appears that FA metabolism, including FA uptake, synthesis, modification, and degradation, are all altered in cancer, which enables cancer cells to proliferate, grow, and disseminate to distant organs.6 While several excellent reviews have covered the general role of lipid metabolism in human cancer,6–12 here, we...
FA metabolism in cancer

Cell proliferation requires that new biological membranes be assembled from lipids. FAs, the building blocks of lipids, can be acquired exogenously (through diet) or endogenously synthesized (Fig. 1). In well-nourished individuals, de novo FA synthesis only minimally contributes to the lipid content of most adult tissues, as normal cells preferentially use exogenous FAs to satisfy their lipid requirements. The uptake of FAs from the circulation is facilitated by protein-mediated transport. Several proteins have been implicated in FA uptake, including fatty acid translocase (FAT)/CD36, fatty acid transport proteins (FATPs)/SLC27A, LDLR, and fatty acid binding proteins (FABPs).

While normal cells primarily depend on the uptake of FAs, cancer cells reactivate de novo FA synthesis, irrespective of circulating lipid levels, which indicates the crucial role played by FA synthesis in tumorigenesis. FA synthesis is an anabolic process that converts nutrient-derived carbons into FAs. These carbons are mainly provided by citrate, which is normally generated from glucose-derived pyruvate flux into the tricarboxylic acid (TCA) cycle. Notably, cancer cells display metabolic plasticity in producing citrate for FA synthesis. During hypoxia or in cancer cells with malfunctioning mitochondria, the TCA cycle is inhibited, and citrate is generated from reductive carboxylation of glutamine-derived α-ketoglutarate by the NADPH-dependent isocitrate dehydrogenase. Through the action of ATP-citrate lyase (ACLY), citrate is cleaved into oxaloacetate and acetyl-coenzyme A (acetyl-CoA), which is the primary substrate for FA synthesis. Next, acetyl-CoA carboxylase (ACC), the rate-limiting enzyme, converts acetyl-CoA into malonyl-CoA. Malonyl-CoA...
is then committed to FA synthesis and is involved in elongation of FA through FASN until palmitate is formed. Additional modification of FAs can be performed by elongases and desaturases to produce FAs at various carbon lengths and levels of saturation. The free FAs are then esterified via the glycerol phosphate pathway to become the hydrophobic tails of phospholipids and sphingolipids, which, together with cholesterol, form key constituents of all biological membranes. FAs can also be used to generate triacylglycerols (TGs) and cholesterol esters (CEs) for energy storage in the form of lipid droplets, which, when necessary, can provide fuel for cellular bioenergetics through FA β-oxidation (FAO). It is worth noting that while the activation of de novo FA synthesis in cancer cells is now widely recognized, the role of exogenous FAs in tumorigenesis has long been underappreciated. Recent studies have demonstrated that many cancer cells also scavenge FAs from their environment, and that de novo synthesis and exogenous FAs are equally important in driving cancer progression, which has substantial implications for cancer treatment (see discussion below).

Expanded role of FA metabolism in cancer

Although aberrant FA metabolism helps explain how cancer cells satisfy their lipid requirements, it is not entirely clear what advantages cancer cells obtain by acquiring more lipids. Recent studies, however, suggest that alterations in FA metabolism, including FA uptake, synthesis, modification and degradation, may play distinctive roles in different metabolic niches and during different stages of tumor development. Here we summarize current knowledge regarding the newly discovered roles played by FA metabolism in tumorigenesis beyond its canonical roles in membrane biosynthesis, energy storage, signal transduction, and post-translational modifications of proteins, which have been reviewed in depth elsewhere.

Protecting cells from lipotoxicity

Viable cells must maintain a proper ratio of saturated to unsaturated FAs in their biological membranes. It has been shown that the accumulation of excess saturated FAs in membranes triggers mitochondrial dysfunction, enhanced reactive oxygen species (ROS), and endoplasmic reticulum (ER) stress. To prevent these outcomes, FA desaturation is carried out by stearoyl-CoA desaturases (SCDs) in an oxygen-dependent manner. Of the two SCD isoforms (SCD1 and SCD5) found in humans, SCD1 is the principle enzyme responsible for desaturation, and is highly expressed in a wide range of tissues. SCD1 converts saturated FAs into mono-unsaturated FAs to increase the levels of unsaturated FAs. Overexpression of SCD1 has been found in tumors of various cancer types, including prostate, breast, liver, kidney, and particularly lung cancer, where it correlates with aggressiveness and reduced patient survival. As a consequence, inhibition of SCD1 can increase the ratio of saturated to unsaturated FAs, leading to ER stress and reduced proliferation in cancer cells. The growth of solid tumors is often characterized by limited concentrations of oxygen, which markedly inhibits the activity of SCD1. To cope with this hypoxic stress, cancer cells scavenge unsaturated FAs from the environment, or release unsaturated FAs from lipid droplets to maintain lipid homeostasis, suggesting that buffering cancer cells from lipotoxicity constitutes a critical function of FA metabolism. Interestingly, Ras-transformed cells also display hypoxic metabolic phenotypes with increased reliance on FA uptake even under normoxic conditions, which may render Ras-driven tumors sensitive to therapies targeting the uptake of FAs.

Impacting cell migration and drug resistance by altering membrane fluidity

The lipid composition of a membrane affects its fluidity: saturated FAs confer a more rigid and organized membrane and decrease membrane fluidity, while unsaturated FAs have at least one cis double bond that distorts the hydrophobic chain, leading to loose membrane packing and a consequent increase in membrane fluidity. Membrane fluidity is a key physical property dictating cell adhesion, migration, and metastatic potential, and recent studies have shown that treatment of breast cancer cells with chemical inhibitors blocking the metastasis signature genes decreases membrane fluidity and inhibits cell migration and lung metastasis. Importantly, addition of oleic acid, an unsaturated FA, to these cancer cells restores previous levels of membrane fluidity and distant metastasis. Furthermore, lung cancer patients with high plasma membrane fluidity generally face a worse prognosis than those with less fluid membranes. Intriguingly, cancer cells with reactivated FA synthesis display high levels of lipid saturation and low membrane fluidity, and are resistant to chemotherapy because of reduced drug uptake, highlighting the positive correlation between membrane fluidity and membrane permeability, and suggesting a possible connection between FA synthesis and drug resistance. Together, these reports indicate how cellular lipids, the end products of lipogenesis, and their composition are altered to change membrane fluidity in support of various aspects of cancer.

Meeting high energy demands of metastatic cells through FAO

Cells that undergo loss of attachment (LOA) to the extracellular matrix display inhibition of glucose uptake and catabolism, which results in loss of cellular ATP. During the invasion-metastasis cascade, metastatic cells exit their primary sites of growth and translocate systemically in the circulation. Therefore, successful
intravasation and extravasation during metastasis require that cancer cells generate or obtain more ATP through some other means. Among metabolic pathways, FAO is the most energy-efficient way to generate ATPs to satisfy the energy needs of cancer cells and is perhaps particularly crucial for disseminated tumor cells, which must withstand the selective pressure of metastatic colonization. Indeed, to survive the colonization process, metastatic ovarian cancer cells catabolize lipids acquired from omental adipocytes to meet their high demand for ATP through FAO.44 Additionally, they also express high levels of monoacylglycerol lipase (MAGL), an enzyme which releases free FAs from lipids. Blockade of MAGL impairs tumor growth and metastasis, which are both rescued by free FAs present in a high fat diet (HFD).45 Furthermore, underscoring the importance of FAO in promoting the aggressiveness of cancer. In addition, a recent study found that a population of metastasis-initiating cells (MICs) express high levels of the FA receptor CD36 and lipid metabolism genes, and are unique in their ability to initiate metastasis.21 CD36 takes lipids up from the extracellular environment, allowing MICs to meet their high demand for ATP through FAO. This is essential for MICs to anchor and survive at metastatic sites. Importantly, administration of a HFD or palmitic acid has been shown to boost the metastatic potential of cancer cells in a CD36-dependent manner. Consistent with these findings, CD36 or its associated gene signature significantly correlates with poor clinical outcomes in patients with cancers of various histological origins.21

The functional significance of FAO in metastatic progression was also recently observed in tumor metastasis to lymph nodes, where researchers found that lymph node metastasis requires that tumor cells undergo a metabolic shift toward FAO, with the transcription coactivator yes-associated protein (YAP) driving the upregulation of FAO-related metabolic genes.46 These studies strongly suggest that inhibition of the FAO metabolic pathway may merit exploration as a potential target for mitigating distant metastasis, which is the leading cause of cancer-related deaths.

Targeting FA metabolism for cancer therapy

As FAs are essential for every aspect of all cellular processes, limiting their availability to cancer cells holds great promise as a therapeutic approach. We will therefore detail below several possible strategies for limiting FA availability to cancer cells (Fig. 1).

Targeting de novo FA synthesis

Considerable efforts have been made to target de novo FA synthesis for cancer treatment as this pathway is of minor importance in normal tissue but is reactivated in cancers of a range of histological origins.6 The expression of the enzymes involved in FA synthesis is mainly regulated by a master transcriptional regulator, the sterol regulatory element binding protein 1 (SREBP-1).47 SREBP-1 has two splice variants: SREBP-1a and SREBP-1c. These activate the FA biosynthetic genes, including ACLY, ACC, FASN, and SCD-1. Therefore, targeting SREBP-1 could inhibit expression levels of lipogenic genes and potentially represent an efficient means of blocking tumor growth. However, targeting transcription factors such as SREBPs remains a daunting task, because they are widely considered undruggable. A potential strategy might be to develop inhibitors targeting the association between SREBP and the SREBP-cleavage activating protein (SCAP), an escort protein that plays an essential role in SREBP activation by mediating ER-to-Golgi transport of SREBP. One example of such an inhibitor is fatostatin, which has been shown to inhibit the growth and metastasis of prostate cancer in preclinical studies.22,48,49 One effect of the inhibition of SREBPs is the loss of SCD-1 expression and consequent FA desaturation, which causes ER stress because of abnormal accumulation of saturated FAs.32,33 Another strategy is to target upstream regulators of SREBPs, such as liver X receptors, which are required for insulin-dependent SREBP-1c transcriptional regulation.50 However, the impacts on cell growth of preventing LXR activation may not be entirely a result of downregulation of SREBP expression alone.

The other way to block FA synthesis is to directly target the enzymes involved in FA synthesis. FASN is the most studied lipogenic enzyme, and its increased expression strongly correlates with poor prognosis in many cancers.7,8 As a result, the FASN inhibitors C75, cerulenin, orlistat, and IPI-9119 have been the subjects of extensive preclinical studies.51–54 However, some FASN inhibitors have produced severe side effects in mice, partly as a result of the essential role of FASN in adult neuronal stem cell function, which has raised concerns regarding their use in the clinic.55,56 And, surprisingly, stable FASN knockdown has been found to enhance cell migration and distant lung metastasis in a xenograft mouse model.57 Although it may seem counterintuitive that suppression of de novo FA synthesis could promote metastasis, it is possible that inhibition of FA biosynthesis during the invasion-metastasis cascade could benefit migratory cells by diverting nutrients and bioenergetics away from anabolic processes and reserving them for cell invasion, suggesting that it is beneficial to target FASN in a tumor-stage dependent manner.

Targeting other enzymes within the FA synthesis pathway has also been evaluated, including ACLY and ACC, and has been shown to inhibit cancer cell growth and proliferation.58–60 Interestingly, through regulation of acetyl-CoA, nuclear ACLY is required for histone acetylation, and may therefore affect cancer cell proliferation on many levels.61 It is worth noting that FAs can not only be synthesized endogenously, but can also be acquired exogenously. Cancer cells take advantage of this metabolic plasticity, which may contribute to rapid drug resistance. Indeed, recent studies have shown...
that lipogenic inhibitors decrease prostate cancer cell viability only in the absence of exogenous lipid sources such as lipoprotein, highlighting the importance of the development of combinatorial treatments.

**Targeting FA modification**

Newly synthesized palmitate can be elongated or desaturated to form a complex collection of FAs. The family of elongases comprises seven members (ELOVL1–7), while the family of desaturases includes only two members (SCD1 and SCD5). Inhibition of ELOVL6 in squamous cell carcinoma cells has been shown to significantly attenuate tumor growth in vivo.63 Meanwhile, inhibition of SCD1 blocks cancer cell growth and proliferation by selectively depleting monounsaturated and polyunsaturated FAs.64–66 Mechanistically, blocking SCD-1 enhances the saturation levels of cardiolipin, a mitochondrial lipid that regulates mitochondria-dependent cell death. As a result, the mitochondria in SCD-1 compromised cells undergo ultrastructural changes, release cytochrome c, and quickly induce cell death. It should be noted that Ras-transformed cells rely on FA uptake to acquire unsaturated FAs and display de novo resistance to SCD1 inhibition.68 Furthermore, some liver and lung carcinomas display metabolic plasticity and employ alternative means to generate unsaturated FAs, that is converting palmitate into sapienate using the FADS2 enzyme, which renders them resistant to SCD1 inhibition.69

**Targeting FA uptake**

In addition to de novo synthesis, cancer cells satisfy their lipid requirements through the uptake of exogenous FAs using various membrane proteins, such as CD36, FATPs, LDLR, and FABPs. Because most lipid chaperones are membrane receptor proteins, targeting FA uptake pathways represents a promising strategy for cancer therapy. Indeed, the CD36 antibody has shown significant anti-tumor or anti-metastatic efficacy in preclinical studies.21,23 Additionally, pharmacological blockade of FATPs with small-molecule inhibitors has been found to abrogate lipid transport into melanoma cells and reduce melanoma growth and invasion.66 FABP4, a mediator of lipid trafficking in adipocytes, is highly expressed in adipocytes and in metastatic ovarian cancer cells at the adipocyte-cancer cell interface, but not in primary ovarian tumors. Either pharmacological inhibition or genetic ablation of FABP4 has been found to drastically inhibit lipid accumulation in ovarian cancer cells and adipocyte-mediated omental metastases.68 These findings suggest that FA uptake and transport will prove another important target pathway for anticancer therapy.

**Targeting FA activation**

FAs must be activated into FA-CoAs by a member of the long-chain acyl-CoA synthetase (ACSL) family before they can be incorporated into either TGs or phospholipids, or broken down into acetyl-CoA to aid ATP generation. In mammals, there are five ACSL members, namely ACSL1, ACSL3, ACSL4, ACSL5, and ACSL6. Targeting these activating enzymes has the advantage of blocking use of FAs regardless of whether they are synthesized de novo or acquired exogenously. However, various roles played by different members of the ACSL family in cancer can be complex. For example, ACSL1 may play a potentially oncogenic role in liver and breast cancer,69,70 but a potentially tumor-suppressive role in lung squamous cell carcinoma.71 While ACSL4 is upregulated in colon, breast, liver, and prostate cancer,72–75 it is downregulated in gastric cancer.76 Therefore, when designing cancer treatment through targeting ACSLs, it is important to consider tissue specificities and the distinctive roles of each ACSL isofrom in cancer. Notably, ACSL4 is also essential for the induction of ferroptosis,77,78 a form of regulated cell death induced by the build-up of toxic lipid peroxides. Induction of ferroptic cell death may represent a therapeutic strategy against various types of cancer with high levels of ACSL4.

**Targeting FA storage and mobilization**

When cellular lipids are in excess, they are diverted to storage as TGs and cholesterol esters in the lipid droplets (LDs), which are specialized organelles with key functions in lipid storage and energy homeostasis.20 LD accumulation has been reported in many cancers and is enhanced in cancer cells exposed to hypoxia or nutrient starvation.79–82 Recent studies have shown that LDs protect cancer cells against nutrient and oxidative stress, contributing to cancer cell survival and growth,80,82 suggesting that LD biogenesis could be an attractive target for strategies designed to diminish the resistance of cancer cells to stress. The inhibition of LD biogenesis may provide a therapeutic advantage by not only increasing lipotoxicity but also concomitantly blocking lipid acquisition and associated survival mechanisms. Emerging studies imply that targeting the molecules involved in LD biogenesis, such as lysophosphatidic-acid acyltransferase 2 (LPCAT2) and FABPs,80,83 holds promise for inhibiting LD formation and tumor growth in vivo.

When needed, the stored lipid esters are mobilized by the action of lipases in a three-step process, catalyzed by adipose triglyceride lipase (ATGL), hormone sensitive lipase (HSL), and monoacylglycerol lipase (MAGL), which releases one FA in each step from the glycerol backbone.84 Although these three lipases have important functions in the adipose tissue, their roles in cancer have not been extensively studied. MAGL is upregulated in several cancers and promotes aggressiveness of cancer through upregulation of endocannabinoid and FA signaling pathways. Knockdown or pharmacological inhibition of MAGL by JZL184 inhibits free FA levels and tumorigenesis of melanoma and ovarian cancer cells.85 The role of ATGL in cancer is relatively complex.
ATGL is overexpressed in high-grade breast tumors and inhibition of ATGL by knockdown or a chemical inhibitor such as atglistatin supresses the growth of several types of cancer cells. Additionally, recent immunohistochemical analysis of ATGL expression in human malignancies has found that ATGL protein levels are significantly reduced in non-small cell lung cancers, pancreatic adenocarcinoma, and leiomyosarcoma compared to adjacent normal tissues. Additionally, mice lacking ATGL spontaneously develop lung tumors. These contradictory results may suggest that the role of ATGL in cancer is dependent on specific tissue types.

**Targeting FA degradation**

FAs provide twice as much ATP as carbohydrates, and as a result are an important energy source for cell growth, survival, and metastasis when nutrients are scarce. Activated FAs are broken down through FAO in mitochondria to generate acetyl-CoA, NADH, and FADH₂. Acetyl-CoA feeds into the TCA cycle, while NADH and FADH₂ enter the electron transport chain to produce ATP. The enzyme carnitine palmitoyl transferase 1 (CPT1) provides the first and rate-limiting step of FA transport into mitochondria for oxidation to carbon dioxide. Knockdown or inhibition of CPT1 by inhibitors (such as etomoxir and ST1326) suppresses cancer cell growth. Interestingly, c-myc-driven cancer appears to be very sensitive to CPT1 inhibition. These data suggest that CPT1 could represent a potential new target for anticaner treatment.

**Conclusions and perspectives**

Cancer cells rely on FAs for all biological activities. Our review provides an update on the expanded role of FA metabolism in cancer as well as emerging opportunities to target this process. FA metabolism can be perceived as a network of pathways notable for its plasticity. This metabolic plasticity has key implications for targeted therapies and subsequent drug resistance. The capability of cancer cells to switch between FA synthesis, FA uptake, and degradation ensures their fitness when exposed to the temporary fluctuations in the availability of nutrients and oxygen. Although chemical inhibitors for specific metabolic pathways already exist, successful therapies targeting FA metabolism may depend on an understanding of the specific metabolic plasticity associated with a particular type of cancer, and may require targeting multiple sources of FAs simultaneously, and perhaps in combination with stringent dietary regimens.

**Acknowledgments**

We extend a sincere apology to those whose work was not discussed or cited in this review because of space limitations. We thank Thomas Garvey for editing the manuscript. This work was supported by the Startup funds at Duke University School of Medicine to M.C. and the National Institutes of Health (Grants No. 5R01CA205001-03 and 5R01CA200853-03) to J.H.

**Conflict of interest**

JH reports advisory roles for Kingmed Diagnostics, Gemflower Healthcare, Optrascan and MoreHealth.

**References**


